3 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 6 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 2, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Unknown 1 |
Follow High-risk: new trials by email Literature Review of High-risk trials Research Report on High-risk
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Guardians Receiving Information Through Navigators Treatment 1: Full GRIN course (Lessons 1-8), Treatment 2: Part 1 of GRIN (Lessons 1-4), Treatment 3: Part 2 of GRIN (Lesson 1, 5-8) - Oral Health, Child | Not applicable | Completed | KDH Research & Communication | 455 | 2025-08-01 | 2026-08-28 |
| Monitoring and Outreach for Maternal Safety Postpartum MOMS Postpartum Course - Postpartum, Women | Not applicable | Completed | KDH Research & Communication | 120 | 2025-03-05 | 2025-07-23 |
| A Cohort Study of Disease Prediction Model for High-risk Population With Bipolar Disorder This was an observational study with no intervention. - High-risk, Bipolar Disorder | Recruiting | Shanghai Mental Health Center | 1200 | 2024-10-15 | 2025-06-22 | |
| Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer Toripalimab, short-term radiotherapy, Oxaliplatin - Locally Advanced, High-Risk | Not applicable | Unknown | Nanfang Hospital, Southern Medical University | 53 | 2023-07-01 | 2023-07-05 |
| A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer stereotactic body radiotherapy - Prostate Cancer, Stereotactic Body Radiotherapy | Not applicable | Unknown | West China Hospital | 60 | 2022-06-30 | 2022-06-24 |
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable Tislelizumab, Nab-paclitaxel - High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 63 | 2020-12-27 | 2021-10-29 |
| Integrative Sequencing In Germline and Hereditary Tumours Hereditary Cancer Syndrome, High-Risk | Active not recruiting | University Health Network, Toronto | 10 | 2018-10-02 | 2025-12-03 | |
| Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma cyclophosphamide, NK cells, hu3F8 - Neuroblastoma, High-Risk | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 85 | 2016-01-05 | 2025-07-30 |
| Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy Immunosuppressive treatment, Tonsillectomy - Primary IgA-nephropathy, High-risk | Not applicable | Recruiting | St. Petersburg State Pavlov Medical University | 240 | 2013-03-10 | 2025-07-20 |
| Enhancing Father's Ability to Support Their Preschool Child Fathers Supporting Success in preschoolers - Fathers, Parenting | Not applicable | Terminated | Queens College, The City University of New York | 125 | 2010-09-01 | 2019-03-27 |
Behavior (1) · Bipolar Disorder (1) · Disease Progression (1) · Glomerulonephritis, IGA (1) · Neoplastic Syndromes, Hereditary (1) · Neuroblastoma (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Neoplasms (4) · Male Urogenital Diseases (2) · Neoplasms by Site (2) · Urogenital Diseases (2) · Autoimmune Diseases (1) · Bipolar and Related Disorders (1) · Colorectal Neoplasms (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
130-nm albumin-bound paclitaxel (1) · Capecitabine (1) · Cyclophosphamide (1) · Oxaliplatin (1) · Radiosurgery (1) · Tonsillectomy (1) · naxitamab (1) · tislelizumab (1) · toripalimab (1)
KDH Research & Communication (2) · Memorial Sloan Kettering Cancer Center (1) · Nanfang Hospital, Southern Medical University (1) · Queens College, The City University of New York (1) · Shanghai Mental Health Center (1) · St. Petersburg State Pavlov Medical University (1) · Tianjin Medical University Second Hospital (1) · University Health Network, Toronto (1) · West China Hospital (1)
China (4) · United States (4) · Canada (1) · Russia (1)
Anil Chacko, PhD (1) · Dehua Wu, MD (1) · Dexter L Cooper (1) · Dexter L Cooper, MPH (1) · Hailong Hu, MD,PhD (1) · Raymond Kim, MD (1) · Shakeel Modak, MD (1) · Vladimir Dobronravov, Professor, MD, PhD, DMedSci (1) · Zinaida Kochoyan, Nephrologist (1)
R43MD019206 (1), R44MD016352 (1)